NY-ESO-1 antibody as a novel tumour marker of gastric cancer

S. Fujiwara, H. Wada, J. Kawada, R. Kawabata, T. Takahashi, J. Fujita, T. Hirao, K. Shibata, Y. Makari, S. Iijima, H. Nishikawa, A. A. Jungbluth, Y. Nakamura, Y. Kurokawa, M. Yamasaki, H. Miyata, K. Nakajima, S. Takiguchi, E. Nakayama, M. MoriY. Doki

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer. Methods: Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone.Results:NY-ESO-1 antibodies were detected in 3.4% of stage I, 4.4% of stage II, 25.3% of stage III, and 20.0% of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2% in stages III and IV, and 5.8% in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses. Conclusion: When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.

Original languageEnglish
Pages (from-to)1119-1125
Number of pages7
JournalBritish journal of cancer
Volume108
Issue number5
DOIs
Publication statusPublished - Mar 19 2013
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'NY-ESO-1 antibody as a novel tumour marker of gastric cancer'. Together they form a unique fingerprint.

Cite this